ArticleOncotarget2014

Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.

Hanyang Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.